---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034183"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-07-22T12:30:27+00:00"
generated_at: "2026-07-22T12:35:18.510347+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies partners with Pictor to develop asthma/COPD diagnostics

## Summary
- Collaboration integrates bioAffinity's flow cytometry with Pictor's targeted proteomic platform for lung inflammation tests.
- Tests aim to match asthma/COPD patients with personalized treatments; asthma/COPD affect 40M Americans and 650M worldwide.
- Global asthma/COPD therapeutics market projected to exceed $108B in 2026 and $155B by 2030.
- bioAffinity will own IP for tests developed; Pictor retains its platform IP and owns new platform inventions.
- Tests initially offered as Laboratory Developed Tests under CLIA; no financial terms disclosed.

## SEC filing metadata
- accession: 0001493152-26-034183
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-07-22T12:30:27+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226034183/0001493152-26-034183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226034183/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034183
- JSON: https://secwatch.observer/filing/0001493152-26-034183.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.